Among these candidate molecular targets, nine were significantly enriched in all three cohorts, and five of them (TP53BP1 [25], RIPK2 [26], EHMT2 [27], IGFBP3 [28], and HMOX1 [29]) have been reported to have cancer- and chemoresistance-promoting activities simultaneously. Here, RIPK2 is linked to cancer.